-
公开(公告)号:US08410082B2
公开(公告)日:2013-04-02
申请号:US13320646
申请日:2010-05-20
申请人: Julie F. Liu , Roger D. Tung , Scott L. Harbeson
发明人: Julie F. Liu , Roger D. Tung , Scott L. Harbeson
CPC分类号: C07D213/81 , C07B59/002
摘要: This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of multiple kinases.
摘要翻译: 本发明涉及新的二芳基脲化合物,其衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用多种激酶抑制剂有益治疗的疾病和病症的方法中的用途。
-
公开(公告)号:US20120237474A1
公开(公告)日:2012-09-20
申请号:US13320646
申请日:2010-05-20
申请人: Julie F. Liu , Roger D. Tung , Scott L. Harbeson
发明人: Julie F. Liu , Roger D. Tung , Scott L. Harbeson
IPC分类号: C07D211/94 , A61P17/00 , A61K39/395 , A61K33/24 , A61K31/56 , A61K31/44 , A61P35/00 , A61P31/12 , A61P29/00 , A61P3/10 , A61P9/12 , A61P19/10 , A61P41/00 , A61P27/02 , A61P27/16 , A61P35/04 , A61P35/02 , A61K38/20
CPC分类号: C07D213/81 , C07B59/002
摘要: This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of multiple kinases.
摘要翻译: 本发明涉及新的二芳基脲化合物,其衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用多种激酶抑制剂有益治疗的疾病和病症的方法中的用途。
-
公开(公告)号:US08987442B2
公开(公告)日:2015-03-24
申请号:US13448930
申请日:2012-04-17
申请人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
发明人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
IPC分类号: A61K31/522 , A61P13/12 , A61P43/00 , C07D473/06
CPC分类号: A61K31/522 , C07D473/06
摘要: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
摘要翻译: 本发明涉及作为取代黄嘌呤衍生物的新化合物及其药学上可接受的盐。 例如,本发明涉及作为己酮可可碱衍生物的新型取代黄嘌呤衍生物。 本发明还提供了包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗己酮可可碱和相关化合物有益的疾病和病症的方法中的用途。
-
公开(公告)号:US20120202830A1
公开(公告)日:2012-08-09
申请号:US13448930
申请日:2012-04-17
申请人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
发明人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
IPC分类号: A61K31/522 , A61P13/12 , A61P43/00
CPC分类号: A61K31/522 , C07D473/06
摘要: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
摘要翻译: 本发明涉及作为取代黄嘌呤衍生物的新化合物及其药学上可接受的盐。 例如,本发明涉及作为己酮可可碱衍生物的新型取代黄嘌呤衍生物。 本发明还提供了包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗己酮可可碱和相关化合物有益的疾病和病症的方法中的用途。
-
公开(公告)号:US20110082147A1
公开(公告)日:2011-04-07
申请号:US12842589
申请日:2010-07-23
申请人: Scott L. Harbeson , Roger D. Tung , Julie F. Liu
发明人: Scott L. Harbeson , Roger D. Tung , Julie F. Liu
CPC分类号: C07D487/04
摘要: This invention relates to novel substituted imidazotriazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound showing partial-agonist activity at the GABA α2, α3 and α5 subtype receptors, and antagonist activity at the al subtype receptor.
摘要翻译: 本发明涉及新的取代的咪唑并嗪及其药学上可接受的盐。 本发明还提供包含本发明化合物的组合物和这些组合物在治疗通过给予在GABAα2,α3和α5亚型受体上显示部分激动剂活性的化合物和拮抗剂有益处理的疾病和病症的方法中的用途 在亚型受体的活性。
-
公开(公告)号:US20110053961A1
公开(公告)日:2011-03-03
申请号:US12873991
申请日:2010-09-01
申请人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
发明人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
IPC分类号: A61K31/522 , C07D473/10 , A61P9/12 , A61P13/12 , A61P1/16 , A61P27/02 , A61P3/10 , A61P3/04
CPC分类号: C07D473/04
摘要: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
-
公开(公告)号:US20140121226A1
公开(公告)日:2014-05-01
申请号:US13949888
申请日:2013-07-24
申请人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
发明人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
IPC分类号: C07D473/04
CPC分类号: C07D473/10 , C07B2200/05 , C07B2200/07 , C07D473/04
摘要: This invention relates to novel deuterated compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are deuterated derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed deuterated compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by the following structural formula: wherein the values of R1, R2, R3, R4, R5, Y1 and Y2 are described herein.
摘要翻译: 本发明涉及新的氘代化合物,其是取代的黄嘌呤衍生物及其药学上可接受的盐。 特别地,本发明涉及作为己酮可可碱代谢物的氘代衍生物的新的取代黄嘌呤衍生物。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所公开的氘代化合物和组合物在治疗己酮可可碱和相关化合物有益的疾病和病症的方法中的用途。 本发明的化合物由以下结构式表示:其中本文描述了R1,R2,R3,R4,R5,Y1和Y2的数值。
-
公开(公告)号:US20140107127A1
公开(公告)日:2014-04-17
申请号:US14030617
申请日:2013-09-18
申请人: Julie F. Liu , Scott L. Harbeson , Roger D. Tung
发明人: Julie F. Liu , Scott L. Harbeson , Roger D. Tung
IPC分类号: C07D471/04
CPC分类号: C07D471/04 , A61K31/4184 , A61K31/4985 , A61K45/06 , Y02A50/411 , Y02A50/423 , A61K2300/00
摘要: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by ad ministering an antihelminthic agent, such as praziquantel.
摘要翻译: 本发明涉及吡嗪并异喹啉衍生物的新化合物及其药学上可接受的盐。 更具体地,本发明涉及作为吡喹酮衍生物的新型吡嗪异喹啉衍生物。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所公开的化合物和组合物在治疗通过使用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。
-
公开(公告)号:US08263601B2
公开(公告)日:2012-09-11
申请号:US12874783
申请日:2010-09-02
申请人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
发明人: Roger D. Tung , Julie F. Liu , Scott L. Harbeson
IPC分类号: C07D473/10 , A61K31/522 , A61P1/16 , A61P13/12 , A61P25/02 , A61P3/10 , C07B59/00
CPC分类号: A61K31/522 , C07D473/06
摘要: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by one of the following structural formulas: wherein the values of R1, R2, Y1 and Y2 are described herein.
摘要翻译: 本发明涉及作为取代黄嘌呤衍生物的新化合物及其药学上可接受的盐。 特别地,本发明涉及作为己酮可可碱代谢物的衍生物的新的取代黄嘌呤衍生物。 本发明还提供了包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗己酮可可碱和相关化合物有益的疾病和病症的方法中的用途。 本发明的化合物由以下结构式之一表示:其中R1,R2,Y1和Y2的值在本文中描述。
-
公开(公告)号:US20110065711A1
公开(公告)日:2011-03-17
申请号:US12820570
申请日:2010-06-22
申请人: Scott L. Harbeson , Roger D. Tung , Julie F. Liu
发明人: Scott L. Harbeson , Roger D. Tung , Julie F. Liu
IPC分类号: A61K31/5025 , C07D487/04 , A61P25/00 , A61P29/00 , A61P19/02
CPC分类号: C07D487/04 , A61K31/5025 , A61K45/06
摘要: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABAA receptor antagonist or an α2- and/or an α3-GABAA receptor partial agonist.
摘要翻译: 本发明涉及新的取代三唑并 - 哒嗪及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用α1-GABA A受体拮抗剂或α2-和/或α3-GABA A受体部分激动剂有益治疗的疾病和病症的方法中的用途 。
-
-
-
-
-
-
-
-
-